Literature DB >> 11926185

Enhanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac.

Francis A Nardella, Jane A LeFevre.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11926185     DOI： 10.1182/blood.v99.7.2625

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

2.  Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro.

Authors:  Elin Lindhagen; Linda Rickardson; Gary Elliott; Lorenzo Leoni; Peter Nygren; Rolf Larsson; Anna Aleskog
Journal:  Invest New Drugs       Date:  2007-04-18       Impact factor: 3.850

3.  In vivo bioavailability and therapeutic assessment of host-guest inclusion phenomena for the hydrophobic molecule etodolac: pharmacodynamic and pharmacokinetic evaluation.

Authors:  Vivek Ranjan Sinha; Honey Goel
Journal:  Sci Pharm       Date:  2010-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.